Premature menopause and cardiovascular disease

Contemporary OB/GYN JournalVol 65 No 1
Volume 65
Issue 01

Women who reach menopause before age 40 may have an increased risk for subsequent cardiovascular disease, according to research from JAMA.

Woman Chest pain

©Adiano -

Both natural and surgical premature menopause before age 40 are associated with a small but statistically significant increased risk for subsequent cardiovascular disease (CVD) compared to that in postmenopausal women without premature menopause, according to a cohort study in JAMA.

The composite outcome included coronary artery disease, heart failure, aortic stenosis, mitral regurgitation, atrial fibrillation, ischemic stroke, peripheral artery disease and venous thromboembolism.

The authors noted that although recent guidelines embrace using history of menopause before age 40 to refine atherosclerotic cardiovascular disease (ASCVD) risk assessments in middle-aged women, “robust data on cardiovascular disease risk in this population is lacking.”

The cohort of 144,260 eligible women was from the large-scale, long-term observational UK Biobank study, comprising adult residents of the United Kingdom recruited between 2006 and 2010. All included women were 40 to 69 years old (mean age 59.9) and postmenopausal at study enrollment, with median follow-up of 7 years through August 2016. Natural premature menopause was defined as menopause before age 40 without oophorectomy, while surgical premature menopause was bilateral oophorectomy before age 40.

Overall, 3.4% (n = 4,903) of women had natural premature menopause and 0.4% (n = 644) had surgical premature menopause. The primary outcome of incidence of composite CVD was 3.9% (n = 5,415) in women with no premature menopause (5.7/1,000 woman-years) and 6.0% (n = 292) in women with natural premature menopause (8.78/1,000 woman-years), representing a difference vs. no premature menopause of +3.08/1,000 woman-years (95% confidence interval [CI]: 2.06 to 4.10; P < 0.001).

Among the 7.6% of women (n = 49) with surgical premature menopause (11.27/1,000 woman-years), the difference vs. no premature menopause was +5.57/1,000 woman-years (95% CI: 2.41 to 8.73; P < 0.001). Overall, natural and surgical premature menopause had hazard ratios of 1.36 (95% CI: 1.19 to 1.56; P < 0.001) and 1.87 (95% CI: 1.36 to 2.58; P < 0.001), respectively, after accounting for conventional CVD risk factors and menopausal hormone therapy.

“These results may have implications for understanding and mitigating the long-term risk for cardiovascular disease associated with premature menopause,” wrote the authors from Massachusetts, Connecticut and Florida. For instance, history of premature menopause allows for primordial prevention, which is a targeted nonpharmacologic strategy to reduce the risk of developing cardiovascular risk factors.

The Framingham Heart Study found that a higher premenopausal Framingham risk factor was linked to earlier age at menopause. The current study, though, concluded that premature menopause may not be limited to comorbid with conventional CVD risk factors, but may separately increase odds of developing these risk factors. In addition, the study found that the CVD risk connected to premature menopause extended beyond ASCVD.

“Postmenopausal state is associated with increase in cytokines and oxidative stress, which may contribute to osteogenesis of valvular interstitial cells,” wrote the authors, noting that it is unknown if this mechanism links premature menopause to aortic stenosis.

Lastly, the form of menopause may be connected to differential cardiovascular risk. Although significant differences in risk between natural and surgical premature menopause were not evident in fully adjusted models, risk differences may arise from differential development of conventional cardiovascular risk facts. There is also the possibility the study had reduced statistical power.

The authors said further research is needed to understand the mechanisms causing the associations between premature menopause and CVD.

Related Videos
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit:
Hot flashes poorly impact sleep quality | Image Credit:
How to manage bone health in midlife women | Image Credit: -
Mary Jane Minkin, MD, discusses The Menopause Society 2023 Annual Meeting | Image Credit: Yale School of Medicine
Highlights from The Menopause Society 2023 Annual Meeting  | Image Credit:
How fezolinetant changes management of hot flashes | Image Credit:
Fezolinetant effective against vasomotor symptoms | Image Credit:
Gloria Richard-Davis MD, MBA, NCMP, FACOG
Related Content
© 2024 MJH Life Sciences

All rights reserved.